natgillin/translations-raw huggingface dataset:
What DOCETAXEL KABI is and what it is used for 
Kaj je zdravilo DOCETAKSEL KABI in za kaj ga uporabljamo
In cases of overdose, exacerbation of adverse events may be expected. 
Pri prevelikih odmerkih je mogoče pričakovati eksacerbacijo neželenih učinkov.
Neutropenic complications in patients receiving TAC with or without primary G-CSF prophylaxis (GEICAM 9805) 
Nevtropenični zapleti pri bolnicah, ki so prejemale TAC z ali brez primarne profilakse z G-CSF (GEICAM 9805)
• fever: if this happens you must tell your doctor immediately 
• povišana telesna temperatura: če se vam to zgodi, morate nemudoma povedati zdravniku,
There is no relevant use of DOCETAXEL KABI in the paediatric population in the indications breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma. 
Zdravilo DOCETAKSEL KABI ni primerno za uporabo pri pediatrični populaciji za indikacije rak dojke, nedrobnocelični pljučni rak, rak prostate, karcinom želodca in rak glave in vratu, ne vključujoč manj diferenciiran nazofaringealni karcinom tipa II oz. III.
Docetaxel plus trastuzumab1 n = 92 
parameter docetaksel in trastuzumab1 n = 92
This regimen was administered every three weeks for 4 cycles in case at least a minor response (≥ 25% reduction in bidimensionally measured tumour size) was observed after 2 cycles. 
To shemo so uporabljali 4 cikle vsake 3 tedne, če so po 2 ciklih opazili vsaj majhen odziv (≥ 25 % zmanjšanje dvodimenzionalno merjene velikosti tumorja).
Disease-free survival (DFS) was the primary efficacy endpoint and Overall survival (OS) was the secondary efficacy endpoint. 
Preživetje brez bolezni (DFS) je bilo primarni, celokupno preživetje (OS) pa sekundarni opazovani dogodek učinkovitosti.
In vivo, docetaxel is schedule independent and has a broad spectrum of experimental anti-tumour activity against advanced murine and human grafted tumours. 
In vivo docetaksel ni odvisen od sheme in ima širok spekter eksperimentalnega protitumorskega delovanja proti napredovalim mišjim in humanim transplantiranim tumorjem.
Blood and lymphatic system disorders Rare: bleeding episodes associated with grade 3/4 thrombocytopenia. 
Bolezni krvi in limfatičnega sistema: Redki: krvavitve povezane s trombocitopenijo stopnje 3/4.
Head and neck cancer 
Rak glave in vratu
• Induction chemotherapy followed by radiotherapy (TAX 323) 
• Indukcijska kemoterapija in nato radioterapija (TAX 323)
DOCETAXEL KABI has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer: - For the treatment of advanced breast cancer, DOCETAXEL KABI could be administered either alone or in combination with doxorubicin, or trastuzumab, or capecitabine. 
Zdravnik vam je zdravilo DOCETAKSEL KABI predpisal za zdravljenje raka dojke, posebne vrste pljučnega raka (nedrobnocelični pljučni rak), raka prostate, raka želodca ali raka glave in vratu: - Za zdravljenje napredovalega raka dojke se lahko zdravilo DOCETAKSEL KABI uporablja sam ali v kombinaciji z doksorubicinom ali trastuzumabom ali kapecitabinom.
The use of docetaxel should be confined to units specialised in the administration of cytotoxic chemotherapy and it should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy (see section 6.6). 
Docetaksel se sme uporabljati le v enotah, specializiranih za citotoksično kemoterapijo in samo pod nadzorom zdravnika, izkušenega na področju onkološke kemoterapije (glejte poglavje 6.6).
The updated analysis was performed when all patients had reached their 10-year (median follow up time of 10 years and 5 months) follow-up visit (unless they had a DFS event or were lost to follow-up previously). 
Posodobljena analiza je bila opravljena, ko so vse bolnice prišle na pregled po 10-letnem (mediani čas spremljanja: 10 let in 5 mesecev) spremljanju (razen če se jim je prej pojavil dogodek DFS ali so se predhodno izgubile spremljanju).
The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates ≥ 10% higher in patients who were 65 years of age or older compared to younger patients. 
Incidenca naslednjih neželenih učinkov (vse stopnje)letargije, stomatitisa in nevtropenične okužbe - je bila pri bolnikih, starih 65 let ali več, ≥ 10 % večja kot pri mlajših bolnikih.
For patients who experience complicated neutropenia (prolonged neutropenia, febrile neutropenia or infection), G-CSF and dose reduction should be considered (see section 4.2). 
Pri bolnicah, ki doživijo komplicirano nevtropenijo (podaljšano nevtropenijo, febrilno nevtropenijo ali okužbo) je potrebno razmisliti o G-CSF in zmanjšanju odmerka (glejte poglavje 4.2).
In the case of severe neutropenia (< 500 cells/mm3 for seven days or more) during a course of docetaxel therapy, a reduction in dose for subsequent courses of therapy or the use of appropriate symptomatic measures are recommended (see section 4.2). 
Če se med zdravljenjem z docetakselom pojavi huda nevtropenija (< 500 celic/mm3 sedem dni ali več), je med naslednjimi cikli priporočljivo zmanjšati odmerek ali uporabiti ustrezne simptomatske ukrepe (glejte poglavje 4.2).
• pneumonia (infection of the lungs) 
• pljučnica (okužba pljuč),
The recommended dose of docetaxel is 75 mg/m2. 
Priporočeno odmerjanje docetaksela je 75 mg/m2.
Docetaxel did not influence the binding of digitoxin. 
Docetaksel ni vplival na vezavo digitoksina.
The primary anticipated complications of overdose would consist of bone marrow suppression, peripheral neurotoxicity and mucositis. 
Glavni pričakovani zapleti prevelikega odmerjanja so supresija kostnega mozga, periferni nevrotoksični učinki in mukozitis.
Second primary malignancies (including acute myeloid leukemia, myelodysplastic syndrome and non-Hodgkin lymphoma) may occur several months or years after docetaxel-containing therapy. 
Drugi primarni malignomi (vključno z akutno mieloično levkemijo, mielodisplastičnim sindromom in ne-Hodgkinovim limfomom) se lahko pojavijo več mesecev ali let po zdravljenju, ki vključuje docetaksel.
Median duration of response to chemotherapy ± radiotherapy (months) (95% CI) 
Mediano trajanje odziva na kemoterapijo ± radioterapijo (meseci) (95 % IZ)
Farnham Road, Bordon Hampshire, GU35 0NF United Kingdom 
Farnham Road, Bordon Hampshire, GU35 0NF Velika Britanija
In combination with trastuzumab the recommended dose of docetaxel is 100 mg/m2 every three weeks, with trastuzumab administered weekly. 
V kombinaciji s trastuzumabom je priporočeni odmerek docetaksela 100 mg/m2 vsake tri tedne, s tedensko aplikacijo trastuzumaba.
Following chemotherapy, patients should receive radiotherapy. 
Po kemoterapiji morajo bolniki prejeti radioterapijo.
Locoregional therapy with radiation was delivered either with a conventional fraction (1.8 Gy - 2.0 Gy once a day, 5 days per week for a total dose of 66 to 70 Gy), or accelerated/hyperfractionated regimens of radiation therapy (twice a day, with a minimum interfraction interval of 6 hours, 5 days per week). 
Lokoregionalno terapijo z obsevanjem so aplicirali bodisi s konvecionalno frakcijo (1,8 Gy - 2,0 Gy enkrat na dan, 5 dni na teden v celotnem odmerku 66 do 70 Gy), ali s pospešenimi/ hiperfrakcioniranimi shemami obsevalnega zdravljenja (dvakrat na dan, z minimalnim intervalom med frakcijama 6 ur, 5 dni na teden).
Fluid retention is cumulative in incidence and severity (see section 4.4). 
Zastajanje tekočine je kumulativno po incidenci in izrazitosti (glejte poglavje 4.4).
At the end of chemotherapy, with a minimal interval of 4 weeks and a maximal interval of 7 weeks, patients whose disease did not progress received radiotherapy (RT) according to institutional guidelines for 7 weeks (PF/RT). 
Na koncu kemoterapije, z minimalnim intervalom 4 tednov in maksimalnim intervalom 7 tednov, so bolniki, katerih bolezen ni napredovala, 7 tednov prejemali radioterapijo (RT) v skladu s smernicami ustanove (PF/RT).
Rare cases of myocardial infarction have been reported. 
Poročali so o redkih primerih miokardnega infarkta.
All patients who did not have progressive disease were to receive chemoradiotherapy (CRT) as per protocol (TPF/CRT). 
Vsi bolniki, ki niso imeli napredujoče bolezni, so dobili kemotradioterapijo (KRT) po protokolu (TPF/KRT).
Overall response rate (%): 
celotni delež odziva (%)
Three docetaxel patients (2%) discontinued the treatment due to fluid retention, whereas 15 doxorubicin patients (9%) discontinued due to cardiac toxicity (three cases of fatal congestive heart failure). 
Tri bolnice (2 %), ki so prejemale docetaksel, so zdravljenje prekinile zaradi zastajanja tekočine, 15 prejemnic (9 %) doksorubicina pa ga je prekinilo zaradi kardiotoksičnih učinkov (trije primeri usodnega kongestivnega srčnega popuščanja).
Very common: Haematological toxicity was increased in patients receiving trastuzumab and docetaxel, compared with docetaxel alone (32% grade 3/4 neutropenia versus 22%, using NCI-CTC criteria). 
Zelo pogosti: Hematoloških toksičnih učinkov je bilo več pri bolnikih, ki so dobivali trastuzumab in docetaksel kot pri tistih, ki so dobivali samo docetaksel (32 % nevtropenije stopnje 3/4 v primerjavi z 22 % po merilih NCI-CTC).
All patients who did not have progressive disease were to receive CRT as per protocol (PF/CRT). 
Vsi bolniki, ki niso imeli napredujoče bolezni, so dobili KRT po protokolu (PF/KRT).
During these two phase III studies, the safety profile of docetaxel was consistent with the safety profile observed in phase II studies (see section 4.8). 
Med študijama III. faze se je varnostni profil docetaksela skladal z varnostnim profilom, ugotovljenim v študijah II.
To be taken into account in pregnant or breast-feeding women, in children and high-risk groups such as patients with liver disease, or epilepsy. 
Vsebnost etanola je treba upoštevati tudi pri nosečnicah, doječih ženskah, otrocih in skupinah z velikim tveganjem, npr. pri bolnikih z boleznijo jeter ali epilepsijo.
Additional cautions for use in adjuvant treatment of breast cancer 
Dodatna opozorila pri uporabi adjuvantne terapije raka dojke
Severe nail disorders are characterised by hypo- or hyperpigmentation and sometimes pain and onycholysis. 
Za hudo prizadetost nohtov so značilni hipo- ali hiperpigmentacija in včasih bolečine in oniholiza.
Radiation was delivered with megavoltage equipment using once daily fractionation (2 Gy per day, 5 days per week for 7 weeks, for a total dose of 70-72 Gy). 
Bolnike so obsevali z megavoltažno opremo s frakcioniranjem enkrat na dan (2 Gy na dan, 5 dni na teden 7 tednov, tako da je bil celotni odmerek 70-72 Gy).
Therefore, men being treated with docetaxel are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment. 
Zato je priporočljivo, da moški, ki se zdravijo z docetakselom, ne zaplodijo otroka med zdravljenjem in v obdobju šestih mesecev po koncu zdravljenja ter da pred začetkom zdravljenja poiščejo nasvet glede ohranitve sperme.
These patients should be closely monitored during initiation of docetaxel therapy. 
Takšne bolnike je treba med uvedbo zdravljenja z docetakselom natančno spremljati.
DOCETAXEL KABI contains alcohol. 
Zdravilo DOCETAKSEL KABI vsebuje alkohol.
DOCETAXEL KABI was administered as a 1-hour infusion, all other medicinal product were given intraveinously on day 1 every three weeks. 
Zdravilo DOCETAKSEL KABI je bilo uporabljeno v 1-urni infuziji, vsa druga zdravila pa intravensko 1. dan na tri tedne.
Docetaxel has been shown to be mutagenic in the in vitro micronucleus and chromosome aberration test in CHO-K1 cells and in the in vivo micronucleus test in the mouse. 
Dokazano je, da je docetaksel mutagen v mikronukleusnem in kromosomskem aberacijskem testu na celicah CHO-K1 in vitro ter v mikronukleusnem testu pri miših in vivo.
Congestive heart failure (CHF) 
Kongestivno srčno popuščanje (KSP)
With primary G-CSF prophylaxis (n = 421) n (%) 
S primarno profilakso z G-CSF (n = 421) n (%)
If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4). 
Če se sočasni uporabi močnega zaviralca CYP3A4 (npr. ketokonazola, itrakonazola, klaritromicina, indinavirja, nefazodona, nelfinavirja, ritonavirja, sakvinavirja, telitromicina ali vorikonazola) ni mogoče izogniti, je potreben natančen klinični nadzor in med zdravljenjem z močnim zaviralcem CYP3A4 je lahko primerna prilagoditev odmerka docetaksela (glejte poglavje 4.4).
Some cases of anaphylactic shock, sometimes fatal, have been reported. 
Poročali so o nekaj primerih anafilaktičnega šoka, včasih usodnega.
However, severe reactions, such as severe hypotension, bronchospasm or generalised rash/erythema require immediate discontinuation of docetaxel and appropriate therapy. 
V primeru hudih reakcij, npr. hude hipotenzije, bronhospazma ali generaliziranega izpuščaja oz. eritema, pa je treba zdravljenje z docetakselom takoj prekiniti in uporabiti ustrezno terapijo.
From a microbiological point of view, reconstitution/dilution must take place in controlled and aseptic conditions. 
Z mikrobiološkega stališča mora biti rekonstitucija/redčenje opravljeno v nadzorovanih in preverjenih aseptičnih pogojih.
Efficacy results are presented in the table below: 
Rezultati učinkovitosti so predstavljeni v spodnji tabeli:
Cases of hyponatraemia have been reported, mostly associated with dehydration, vomiting and pneumonia. 
Opisani so bili primeri hiponatriemije, večinoma povezani z dehidracijo, bruhanjem in pljučnico.
Subset Analyses-Adjuvant Therapy in Patients with Node-negative Breast Cancer Study (Intent-to-Treat Analysis) 
Analize podskupine - adjuvantno zdravljenje bolnic v študiji raka dojke z negativnimi bezgavkami (analiza z-namenom-zdravljenja)
Although the possible in vivo interaction of docetaxel with concomitantly administered medicinal product has not been investigated formally, in vitro interactions with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone, phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein binding of docetaxel. 
Možna medsebojna delovanja docetaksela s sočasno uporabljanimi zdravili in vivo sicer niso bila formalno raziskana, a medsebojno delovanje z učinkovinami, močno vezanimi na beljakovine - npr. eritromicinom, difenhidraminom, propranololom, propafenonom, fenitoinom, salicilati, sulfametoksazolom in natrijevim valproatomin vitro ni vplivalo na vezavo docetaksela na beljakovine.
Acute leukaemia / Myelodysplastic syndrome 
Akutna levkemija/mielodisplastični sindrom:
General disorders and administration site conditions The median cumulative dose to treatment discontinuation was more than 1,000 mg/m2 and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks). 
Mediani kumulativni odmerek do prekinitve zdravljenja je bil več kot 1.000 mg/m2 in mediani čas do izginotja zastoja tekočine 16,4 tedna (razpon od 0 do 42 tednov).
The onset of moderate and severe retention is delayed (median cumulative dose: 818.9 mg/m2) in patients with premedication compared with patients without premedication (median cumulative dose: 489.7 mg/m2); however, it has been reported in some patients during the early courses of therapy. 
Zmeren oz. hud zastoj se kasneje pojavi pri bolnikih, ki dobijo premedikacijo (mediani kumulativni odmerek: 818,9 mg/m2), kot pri tistih, ki je ne (mediani kumulativni odmerek: 489,7 mg/m2); vendar je pri nekaterih bolnikih opisan med zgodnjimi cikli zdravljenja.
Previous chemotherapy should have included an anthracycline or an alkylating agent. 
Predhodna kemoterapija bi morala vključevati antraciklin ali alkilirajočo učinkovino.
If hypersensitivity reactions occur, minor symptoms such as flushing or localised cutaneous reactions do not require interruption of therapy. 
V primeru blažjih preobčutljivostnih reakcij, npr. pordevanja ali lokalnih kožnih reakcij, zdravljenja ni treba prekiniti.
In the pivotal SCCHN studies patients who experienced complicated neutropenia (including prolonged neutropenia, febrile neutropenia, or infection), it was recommended to use G-CSF to provide prophylactic coverage (eg, day 6-15) in all subsequent cycles. 
V ključnih študijah SCCHN pri bolnikih, pri katerih se je pojavila komplicirana nevtropenija (ki vključuje dolgotrajno nevtropenijo, febrilno nevtropenijo ali okužbo), je bilo priporočeno, naj se v vseh naslednjih ciklih za profilaktično kritje (na primer med 6. in 15. dnem) uporablja G-CSF.
The kinetic profile of docetaxel is dose independent and consistent with a three-compartment pharmacokinetic model with half lives for the α, β and γ phases of 4 min, 36 min and 11.1 h, respectively. 
Kinetični profil docetaksela ni odvisen od odmerka in se sklada s trirazdelčnim farmakokinetičnim modelom, pri čemer je razpolovni čas faze α 4 minute, ß 36 minut in γ 11,1 ure.
• blurred vision due to swelling of the retina within the eye (cystoid macular oedema) 
• zamegljen vid zaradi oteklosti očesne mrežnice (cistoidni makularni edem),
• feeling of numbness or pins and needles or pain in the joints or muscles 
• občutek omrtvelosti, mravljinčenje ali bolečine v sklepih ali mišicah,
Consequently, because of the potential for adverse reactions in nursing infants, breast feeding must be discontinued for the duration of docetaxel therapy. 
Zaradi možnih neželenih učinkov na dojenčke je treba dojenje med zdravljenjem z docetakselom prekiniti.
Injection site recall reaction (recurrence of skin reaction at a site of previous extravasation following administration of docetaxel at a different site) has been observed at the site of previous extravasation (frequency not known). 
Na mestu prejšnje ekstravazacije so opažali reakcijo pomnjenja na mestu injiciranja (ponovitev kožne reakcije na mestu predhodne ekstravazacije med dajanjem docetaksela na druge mestu) (pogostnost ni znana).
If you are a man being treated with DOCETAXEL KABI you are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because docetaxel may alter male fertility. 
Če ste moški, ki se zdravi z zdravilom DOCETAKSEL KABI je priporočljivo, da ne zaplodite otroka med zdravljenjem in v obdobju 6 mesecev po koncu zdravljenja ter da pred začetkom zdravljenja poiščete nasvet glede ohranitve sperme, ker docetaksel lahko prizadene moško plodnost.
Patients with operable node-negative breast cancer eligible to receive chemotherapy (GEICAM 9805) 
Bolnice z operabilnim rakom dojke z negativnimi bezgavkami, primerne za prejemanje kemoterapije (GEICAM 9805)
Very rare cases of transient visual disturbances (flashes, flashing lights, scotomata) typically occurring during infusion of the medicinal product and in association with hypersensitivity reactions have been reported. 
Opisani so bili zelo redki primeri prehodnih motenj vida (bliskanje, bliskajoča svetloba, skotomi), ki so se praviloma pojavili med infundiranjem zdravila in v povezavi s preobčutljivostnimi reakcijami.
Based on a population pharmacokinetic analysis, there are no special instructions for use in the elderly. 
Za uporabo pri starejših bolnikih glede na analizo farmakokinetike na populaciji ni posebnih navodil.
In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by 
V farmakokinetični študiji s 7 bolnicami je sočasna uporaba docetaksela in močnega zaviralca CYP3A4 ketokonazola zmanjšala očistek docetaksela za 49 %.
Renal insufficiency and renal failure have been reported. 
Opisani sta bili ledvična insuficienca in odpoved ledvic.
• As with all parenteral products, infusion solution should be visually inspected prior to use, solutions containing a precipitate should be discarded. 
• Tako kot vsa zdravila za parenteralno uporabo je treba tudi raztopino za infundiranje pred uporabo pregledati; če vsebuje precipitat, jo je treba zavreči.
The incidence of related fever, diarrhoea, anorexia, and peripheral oedema occurred at rates ≥ 10% higher in patients who were 75 years of age or greater versus less than 65 years. 
Incidenca z zdravljenjem povezane povišane telesne temperature, diareje, anoreksije in perifernih edemov se je pojavljala ≥ 10 % večkrat pri bolnikih nad 75 let v primerjavi z mlajšimi od 65 let.
Docetaxel is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing its solutions. 
Docetaksel je antineoplastična učinkovina in tako kot pri ravnanju z drugimi potencialno toksičnimi spojinami je tudi med rokovanjem z njim in med pripravo njegovih raztopin potrebna previdnost.
• Mitoxantrone 12 mg/m2 every 3 weeks for 10 cycles. 
• Mitoksantron 12 mg/m2 vsake 3 tedne, 10 ciklov.
If subsequent episodes of complicated neutropenia occur the docetaxel dose should be reduced from 60 to 45 mg/m2. 
Če se pojavijo nadaljnje epizode zapletene nevtropenije, je treba odmerek docetaksela zmanjšati s 60 na 45 mg/m2.
Median time to first deterioration of WHO performance status was significantly longer in the TPF arm compared to PF. 
Mediani čas do prvega poslabšanja stanja zmogljivosti po WHO je bil signifikantno daljši v kraku TPH kot v kraku PF.
• dehydration 
• dehidracija,
In patients treated with the TAC regimen for node positive breast cancer, the risk of CHF has been shown to be higher during the first year after treatment (see sections 4.8 and 5.1). 
Bolnice, ki so bile zaradi raka dojke s pozitivnimi bezgavkami zdravljene s shemo TAC, so imele v prvem letu po zdravljenju večje tveganje kongestivnega srčnega popuščanja (glejte poglavji 4.8 in 5.1).
Your doctor may stop your treatment immediately. 
Vaš zdravnik se bo morda odločil prekiniti zdravljenje.
What you need to know before you use DOCETAXEL KABI 
Kaj morate vedeti, preden boste uporabili zdravilo DOCETAKSEL KABI
If the vials are stored under refrigeration, allow the required number of boxes of DOCETAXEL KABI concentrate for solution for infusion to stand below 25°C for 5 minutes before use. 
Če so viale shranjene v hladilniku, pustite potrebno število škatel koncentrata za raztopino za infundiranje zdravila DOCETAKSEL KABI pred uporabo 5 minut stati na temperaturi do 25°C.
Docetaxel clearance was not modified in patients with mild to moderate fluid retention and there are no data available in patients with severe fluid retention. 
Pri bolnikih z blagim do zmernim zastajanjem tekočine se očistek docetaksela ni spremenil; za bolnike s hudim zastajanjem tekočine podatkov ni.
• Then, inject via a single injection (one shot) into a 250 ml infusion bag or bottle containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion. 
• Potem jo vbrizgajte preko ene injekcije (en odmerek) v 250 ml infuzijsko vrečo ali steklenico, ki vsebuje 5 % raztopino glukoze ali raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
• inflammation of the eye or increased tearing of the eyes 
• vnetje oči ali močnejše solzenje,
Toxic deaths occurred in 1 patient in the AT arm (congestive heart failure) and in 4 patients in the AC arm (1 due to septic shock and 3 due to congestive heart failure). 
Do smrti zaradi zastrupitve je prišlo pri 1 bolnici v kraku AT (kongestivno srčno popuščanje) in 4 bolnicah v kraku AC (pri 1 zaradi septičnega šoka, pri 3 zaradi kongestivnega srčnega popuščanja).
Patients who have developed severe hypersensitivity reactions should not be re-challenged with docetaxel. 
Bolniki, ki so doživeli hudo preobčutljivostno reakcijo, ne smejo več dobiti docetaksela.
Neutropenic infection 
Nevtropenična okužba